MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer. - Wikidata - wikimedia - TriplyDB

MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer.

MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer.

http://www.wikidata.org/entity/Q53275543

about

Ribociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.Breast cancer complexity: implications of intratumoral heterogeneity in clinical management.Abemaciclib: First Global Approval.Emerging data on improving response to hormone therapy: the role of novel targeted agents.CDK4/6 dual inhibitor abemaciclib demonstrates compelling preclinical activity against esophageal adenocarcinoma: a novel therapeutic option for a deadly disease.Recent advances of cyclin-dependent kinases as potential therapeutic targets in HR+/HER2- metastatic breast cancer: a focus on ribociclib.Efficacy of palbociclib plus fulvestrant after everolimus in hormone receptor-positive metastatic breast cancer.Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions.Incorporating CDK4/6 Inhibitors in the Treatment of Advanced Luminal Breast Cancer.Hematological adverse effects in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis.Strategies and Progress of Endocrine Therapy for Patients with Metastatic Breast Cancer.A single institution experience with palbociclib toxicity requiring dose modifications.Efficacy and safety of palbociclib in heavily pretreated patients with HR+/HER2- metastatic breast cancer.Potential biomarkers of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer.New agents for the management of resistant metastatic breast cancer.Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2− advanced breast cancer.Deciphering the binding behavior of flavonoids to the cyclin dependent kinase 6/cyclin D complex.The role of abemaciclib in treatment of advanced breast cancer.Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer.Precision Medicine in Hormone Receptor-Positive Breast Cancer.Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer Profile of abemaciclib and its potential in the treatment of breast cancer Progress in targeted therapy for breast cancer

P2860

Q38649485-4F452222-C501-49C0-9E69-B3F3A298E1EC Q38656112-B22A046E-358F-41A3-8F47-825CE3528DBE Q43280771-EC808661-3829-4D44-A092-DE5EA07D6B59 Q46537162-A2A8A07E-6B6F-4AE2-AAF5-F4D97F35871C Q47142001-A4DB7D79-ECDC-4183-A2A0-4555F7FF5FB3 Q47169141-90291CD6-299C-4A86-8881-CC956D1012BC Q47299171-06DCE41C-347A-4D05-AD88-DA63627AC9C6 Q47316489-151DEB42-A9AB-442B-9392-260FAD72C0A1 Q47321026-D0188357-1019-4A9C-8625-71331B9F1C25 Q47393206-EFF4A411-E4F1-4C27-95E6-57DB86F6BA85 Q47561979-9D4B1BAB-ADB1-4983-B128-46A8614216C2 Q47563304-3AC8D415-7E8D-4AF5-83D4-721F462439C6 Q47823987-68207894-B059-4056-8032-2B8A2C7AB1DC Q48125385-BC954793-BCCD-4394-ADDB-3B125D120649 Q48240854-8345E21E-EE46-477E-932A-DE1982280161 Q50333196-890DBFB6-D7D4-41CF-82C8-BCECBD10873D Q54979952-242627D8-A5FC-4D15-802D-FA006FFCE743 Q55124984-81D7D03B-3BC3-491A-843D-9856AF03EC4A Q55310990-AE203B0C-B99C-4BD5-A873-C98176210025 Q55379220-CF12F592-B6A5-46D1-8D51-8E7AF9243AB3 Q57106504-F3721EE3-02F2-44FD-8743-3AC356B373A1 Q57107448-72603D5C-C206-456A-9EBC-AC8E5C9C892C Q57109788-465E3CFF-08C7-48E0-9110-C53602E62FE5

P2860

MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer.

http://www.wikidata.org/entity/Q53275543

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

MONARCH 1, A Phase II Study of ...... ER2- Metastatic Breast Cancer.

@en

MONARCH 1, A Phase II Study of ...... ER2- Metastatic Breast Cancer.

@nl

type

label

MONARCH 1, A Phase II Study of ...... ER2- Metastatic Breast Cancer.

@en

MONARCH 1, A Phase II Study of ...... ER2- Metastatic Breast Cancer.

@nl

prefLabel

MONARCH 1, A Phase II Study of ...... ER2- Metastatic Breast Cancer.

@en

MONARCH 1, A Phase II Study of ...... ER2- Metastatic Breast Cancer.

@nl

P1433

Q53275543-3C0B33D0-377A-46B5-A8C4-059EC583C18D

P1476

Q53275543-C1F4B7E9-2927-4EFC-B2A6-2A85F295CF10

P2093

Q53275543-0C5CBDF9-7D0E-4C95-BB67-CBEA4B356B9C

Q53275543-1DA6C568-0296-492F-82EE-DB1AB3020A95

Q53275543-3C1E37A8-7E1E-4F89-9170-077706CAD2FD

Q53275543-42A58FDB-4959-41AA-BD2D-A4D5BE4806FE

Q53275543-46496280-7866-45FF-B94F-083062847842

Q53275543-578A1B0A-0007-4837-829A-96FF653943A2

Q53275543-5C57611E-668F-48DD-8277-A63D8A62A49B

Q53275543-7000334B-4A01-47E3-B03A-164982C178CA

Q53275543-AEE57A5B-EAE4-4C7A-B77E-61BEFCB0A05B

Q53275543-AF80CE01-3FF9-4CAC-8A34-E051DA61593A

P2860

Q53275543-03B59403-E9FF-48B7-A9F6-78613D9E0AE9

Q53275543-11A0525E-67B3-4F84-96B3-05D48291E5DE

Q53275543-24E5934E-0CA6-4E57-A7AB-0C154CA8B983

Q53275543-2676DF07-DE81-44FA-A7A7-8EB98B9CF49E

Q53275543-2D432E37-0D32-4285-BA79-466D886DA36F

Q53275543-2D7768B6-ECF0-4612-B15E-373ACF866542

Q53275543-4528A2CC-F40B-47BD-B701-93B69EBBD7B4

Q53275543-46E209D6-154D-4406-BD32-00B51C11E3D6

Q53275543-491057BA-9986-4D76-A41C-06EBD4DBBB64

Q53275543-521D3F09-2E9E-4E26-A8A4-58E44F501AA8

P304

Q53275543-6B186294-B922-48FE-8ADF-11EC2E844895

P31

Q53275543-96C142E9-F350-4E6F-8219-414347A0F1EF

P356

Q53275543-ECCE74BD-B006-42E0-A210-9FB542338C05

P407

Q53275543-A47003CA-CCFD-4C37-A7A0-32BD477BB767

P433

Q53275543-C48EDE6C-A3E9-495B-BD3B-14805AAC6605

P478

Q53275543-7AECDB6E-BF07-43F9-8355-279400FA5738

P50

Q53275543-FD38B92A-D8F5-4498-A277-89AF430C6DBC

P577

Q53275543-72596575-5A56-461E-8161-8447FC7D48A8

P698

Q53275543-3DC6F777-FA63-4957-A37B-FFF46A134CC7

P932

Q53275543-AC1E2013-9B14-432D-8C87-0ED6FC1D822F

P356

1078-0432.CCR-17-0754

P1433

Clinical Cancer Research

P1476

MONARCH 1, A Phase II Study of ...... ER2- Metastatic Breast Cancer.

@en

P2093

Andrew Koustenis

http://www.w3.org/2001/XMLSchema#string

Clifford A Hudis

http://www.w3.org/2001/XMLSchema#string

Debra Patt

http://www.w3.org/2001/XMLSchema#string

Denise A Yardley

http://www.w3.org/2001/XMLSchema#string

Esther Zamora

http://www.w3.org/2001/XMLSchema#string

Hans Wildiers

http://www.w3.org/2001/XMLSchema#string

Hope S Rugo

http://www.w3.org/2001/XMLSchema#string

José Baselga

http://www.w3.org/2001/XMLSchema#string

Joyce O'Shaughnessy

http://www.w3.org/2001/XMLSchema#string

Martin Frenzel

http://www.w3.org/2001/XMLSchema#string

P2860

Cell cycle, CDKs and cancer: a changing paradigm

Cytotoxic chemotherapy: Still the mainstay of clinical practice for all subtypes metastatic breast cancer

Enhancing Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: Cotargeting Signaling Pathways

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Cyclin D as a therapeutic target in cancer

Requirement for CDK4 kinase function in breast cancer

CDK6 as a key regulator of hematopoietic and leukemic stem cell activation

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Breast Cancer: A Review of Preclinical and Clinical Data.

CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment.

P304

5218-5224

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-17-0754

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-05-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28533223

http://www.w3.org/2001/XMLSchema#string

P932

5581697

http://www.w3.org/2001/XMLSchema#string